The gamma-aminobutyric acid type B (GABA-B) receptor is the sole member of the metabotropic GABA receptor family and represents the first discovered G protein-coupled receptor (GPCR) of the class C family. Unlike GABA-A receptors, which are ionotropic chloride channels mediating fast inhibitory neurotransmission, GABA-B receptors are metabotropic receptors that activate Gi/o proteins, leading to slow, sustained inhibitory effects through presynaptic inhibition of neurotransmitter release and postsynaptic hyperpolarization through activation of potassium channels. These receptors are widely expressed in the central nervous system (CNS), where they play critical roles in regulating neuronal excitability, synaptic plasticity, and network oscillations. GABA-B receptors are implicated in various neurological and psychiatric disorders, including epilepsy, spasticity, addiction, and are increasingly recognized as potential therapeutic targets in neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) .
| GABA-B Receptor |
|---|
| Protein Name | GABA-B Receptor (GABABR) |
| Gene Symbols | GABBR1, GABBR2 |
| UniProt IDs | [P31178](https://www.uniprot.org/uniprot/P31178) (GABBR1), [O75899](https://www.uniprot.org/uniprot/O75899) (GABBR2) |
| PDB Structures | 4MQE, 5CGC, 5VAI, 6VZ3 |
| Molecular Weight | GABBR1: 110 kDa; GABBR2: 97 kDa |
| Length | GABBR1: 961 aa; GABBR2: 881 aa |
| Subcellular Localization | Plasma membrane (postsynaptic and presynaptic) |
| Protein Family | Class C GPCR, metabotropic glutamate receptor family |
| Expression | High in cortex, hippocampus, cerebellum, spinal cord |
GABA-B receptors are obligate heterodimers composed of two distinct subunits, GABBR1 (also called GABA-B1) and GABBR2 (also called GABA-B2). Neither subunit is functional on its own; heterodimerization is required for proper receptor trafficking to the plasma membrane and functional signaling.
The GABBR1 subunit contains the ligand-binding extracellular Venus flytrap domain (VFD) and is responsible for binding the endogenous agonist GABA, as well as the allosteric modulator baclofen. The GABBR1 subunit has two major isoforms generated by alternative splicing:
GABBR1a (long isoform)
- Contains an N-terminal sushi domain (also called the cysteine-rich domain)
- Predominantly presynaptic, regulating neurotransmitter release
- The sushi domain may interact with RGS proteins and influence receptor trafficking
GABBR1b (short isoform)
- Lacks the sushi domain
- More evenly distributed between presynaptic and postsynaptic compartments
- Mediates both pre- and postsynaptic GABA-B responses
The GABBR2 subunit lacks a functional extracellular ligand-binding domain but contains the seven transmembrane domains typical of GPCRs and is responsible for coupling to Gi/o proteins. The intracellular C-terminal tail of GABBR2 contains motifs required for:
- G protein coupling
- Arrestin binding
- Receptor internalization
- Interactions with scaffolding proteins
The GABA-B heterodimer forms through interactions between:
- The transmembrane domains of both subunits (formation of the 7TM bundle)
- The C-terminal coiled-coil domain (critical for stable heterodimerization)
The extracellular Venus flytrap domains of each subunit come into close proximity upon agonist binding, undergoing a conformational change that is transmitted through the transmembrane domains to the GABBR2 subunit, activating G protein signaling.
The GABA-B receptor undergoes a characteristic " Venus flytrap" mechanism of activation:
- Resting state: The VFDs of both subunits are separated, with the agonist binding pocket in an open, low-affinity conformation
- Agonist binding: GABA binds to the VFD of GABBR1, stabilizing the closed, high-affinity conformation
- Interface closure: The closed VFD of GABBR1 engages the VFD of GABBR2, causing it to also close
- Transmembrane transmission: The closure of the extracellular domains pulls on the transmembrane helices, creating a rearrangement in the 7TM bundle
- G protein activation: The conformational change in the 7TM domain allows G protein coupling and activation
GABA-B receptors on presynaptic terminals regulate neurotransmitter release through two primary mechanisms:
Inhibition of Voltage-Gated Calcium Channels
- Activation of Gβγ subunits inhibits P/Q-type (Cav2.1) and N-type (Cav2.2) calcium channels
- Reduces Ca²⁺ influx into presynaptic terminals
- Decreases vesicle fusion probability and neurotransmitter release
Inhibition of Vesicle Release Machinery
- Gβγ subunits can directly interact with the release machinery
- Reduces synaptic vesicle pool mobilization
- Provides tonic inhibition of neurotransmitter release
The presynaptic GABA-B receptor serves as an autoreceptor (responding to GABA released from the same neuron) and heteroreceptor (modulating release of other neurotransmitters like glutamate, serotonin, norepinephrine).
On postsynaptic neurons, GABA-B receptors mediate slow inhibitory responses:
Activation of Inwardly Rectifying K⁺ Channels
- GABA-B activation opens G protein-coupled inward rectifier potassium (GIRK) channels
- Causes membrane hyperpolarization
- Increases threshold for action potential generation
- Produces IPSPs (inhibitory postsynaptic potentials) lasting 100-500 ms
Inhibition of Adenylate Cyclase
- Gi/o protein inhibition of adenylate cyclase reduces cAMP levels
- Modulates various downstream signaling pathways
- Affects neuronal excitability and gene expression
GABA-B receptors modulate several important network oscillations and processes:
Theta Oscillations: GABA-B activity contributes to theta rhythm generation in the hippocampus, important for spatial memory and navigation.
Gamma Oscillations: Modulation of interneuron networks influences gamma oscillations (30-80 Hz), critical for cognitive processing.
Epileptiform Activity: GABA-B receptors help limit seizure spread through their inhibitory actions on excitatory networks.
GABA-B receptor signaling is altered in Alzheimer's disease through multiple mechanisms:
Excitatory-Inhibitory Imbalance
In AD, there is generally a shift toward reduced GABAergic inhibition, which paradoxically can increase network hyperexcitability and seizure risk. However, GABA-B receptors may show altered expression or function:
- Reduced GABBR1 and GABBR2 expression in hippocampus and cortex of AD patients
- Impaired GABA-B-mediated inhibition contributes to hippocampal hyperexcitability
- Increased susceptibility to seizures in AD patients
Amyloid Interaction
Amyloid-beta (Aβ) peptides directly interact with GABA-B receptors:
- Aβ oligomers bind to GABA-B receptors, impairing their function
- This interaction contributes to synaptic dysfunction
- GABA-B agonists can partially rescue Aβ-induced synaptic deficits
Tau Pathology
GABA-B receptor expression is reduced in brain regions with high tau pathology:
- The entorhinal cortex and hippocampus show particular vulnerability
- Loss of GABA-B function may contribute to navigation deficits
Therapeutic Potential
GABA-B agonists (e.g., baclofen) are being explored in AD:
- May reduce network hyperexcitability
- Could improve cognitive function through enhanced inhibition
- May have neuroprotective effects through reduced excitotoxicity
In Parkinson's disease, GABA-B receptors play complex roles in both motor and non-motor symptoms:
Motor Symptoms
- GABA-B activity in the basal ganglia helps regulate movement
- Altered GABA-B signaling contributes to akinesia and rigidity
- GABA-B agonists may provide modest benefit for motor symptoms
L-DOPA-Induced Dyskinesias
GABA-B receptors are emerging as targets for managing L-DOPA-induced dyskinesias (LID):
- GABA-B activation reduces striatal dopamine release
- May modulate the glutamatergic overactivity that underlies LID
- Baclofen has shown efficacy in reducing dyskinesias in clinical trials
Non-Motor Symptoms
GABA-B dysfunction contributes to:
- REM sleep behavior disorder
- Autonomic dysfunction
- Cognitive impairment
GABA-B receptors are critically involved in seizure pathophysiology:
Aberrant Network Excitability
- Loss of GABA-B-mediated inhibition contributes to seizure generation
- GABA-B agonists (baclofen) can suppress seizure activity
- However, tolerance develops with chronic use
Absence Seizures
GABA-B receptors in thalamocortical circuits contribute to spike-and-wave discharges characteristic of absence seizures.
Temporal Lobe Epilepsy
- GABA-B expression is altered in the epileptic hippocampus
- Dysfunction contributes to hyperexcitability and spontaneous seizures
¶ Spasticity and Multiple Sclerosis
GABA-B agonists (particularly baclofen) are used clinically to treat spasticity:
- Activate spinal GABA-B receptors
- Reduce alpha motor neuron excitability
- Decrease muscle tone and clonus
In MS, GABA-B modulation may also have neuroprotective effects through modulation of immune responses.
GABA-B receptors are involved in the neurobiological basis of addiction:
Alcohol Use Disorder
- Baclofen reduces alcohol craving and consumption
- May normalize GABAergic signaling in reward circuits
- FDA-approved for alcohol use disorder in some countries
Cocaine and Other Stimulants
- GABA-B modulation reduces cocaine-seeking behavior
- May attenuate reward-driven behaviors
flowchart TD
A["GABA<br/>Agonist"] --> B["GABBR1<br/>Ligand Binding"]
B --> C["Heterodimer<br/>Activation"]
C --> D{"Gi/o Protein<br/>Signaling"}
D --> E["Inhibition of<br/>Adenylate Cyclase"]
E --> F["↓ cAMP"]
F --> G["Reduced PKA<br/>Activity"]
D --> H["Gβγ Subunit<br/>Release"]
H --> I["KIRK Channel<br/>Activation"]
I --> J["K⁺ Outward Flow"]
J --> K["Hyperpolarization"]
H --> L["Cav2.1/Cav2.2<br/>Inhibition"]
L --> M["↓ Ca²⁺ Influx"]
M --> N["Reduced<br/>Neurotransmitter<br/>Release"]
D --> O["ERK1/2<br/>Pathway"]
O --> P["Gene<br/>Transcription"]
style A fill:#e1f5fe,stroke:#333
style K fill:#c8e6c9,stroke:#333
style N fill:#c8e6c9,stroke:#333
Baclofen
- Classic GABA-B agonist used for spasticity
- Crosses the blood-brain barrier moderately well
- Side effects include sedation, dizziness, and tolerance
- Being repurposed for addiction and dyskinesias
Phenibut
- GABA-B agonist with anxiolytic effects
- Used in some countries for anxiety and insomnia
- Risk of dependence with chronic use
CGP55845 and CGP54626
- Experimental GABA-B agonists
- Used in research settings
GABA-B PAMs offer potential advantages over agonists:
Advantages:
- Preserve temporal and spatial specificity of endogenous GABA signaling
- Reduced risk of tolerance development
- Fewer side effects (they don't directly activate the receptor)
Examples-BHFF, GS-39783, ADX-71441
Clinical Potential:
- Anxiety disorders
- Substance use disorders
- Cognitive enhancement
- Neuroprotection
SCH-50911
- Selective GABA-B antagonist
- Used in research to understand receptor function
- May have pro-cognitive effects by enhancing glutamate release
Viral vector delivery of GABA-B components is being explored:
- AAV-mediated delivery to enhance GABA-B signaling
- Targeting specific brain regions
- May provide more continuous and localized therapy
Side Effects
- Sedation, dizziness, fatigue
- Tolerance development with agonists
- Respiratory depression (especially with high doses)
Blood-Brain Barrier Penetration
- Many compounds have limited CNS penetration
- Developing brain-penetrant compounds is an active area
Receptor Desensitization
- Chronic agonist exposure leads to receptor desensitization
- PAMs may avoid this issue
- Bettler et al., Molecular structure and physiological functions (2004) — Comprehensive review of GABA-B receptor biology
- Pin et al., Evolution and structure of class 3 GPCRs (2003) — Structural basis of metabotropic receptor activation
- Cryan et al., GABA(B) receptor isoforms (2004) — Isoform-specific functions and drug discovery opportunities
- Gassmann et al., Redistribution of GABA-B protein (2010) — Role of GABBR1a isoform
- Bowery et al., GABA(B) receptors: first of the metabotropic family (2006) — Historical perspective and receptor classification
- Ulrich & Bettler, GABA(B) receptor functions in the CNS (2022) — Recent comprehensive review
- Shen et al., GABA(B) receptor activity modulation (2019) — Neurodegenerative disease implications
- Li et al., GABA(B) receptor agonists for AD (2023) — Therapeutic potential in Alzheimer's disease
- Frangaj & Fan, Structural biology of metabotropic GABA(B) receptors (2021) — Recent structural insights